摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-Methylthio-3-carbethoxy-4-chinolinol | 26893-10-7

中文名称
——
中文别名
——
英文名称
7-Methylthio-3-carbethoxy-4-chinolinol
英文别名
ethyl 4-hydroxy-7-(methylsulfanyl)-3-quinolinecarboxylate;ethyl 7-methylsulfanyl-4-oxo-1H-quinoline-3-carboxylate
7-Methylthio-3-carbethoxy-4-chinolinol化学式
CAS
26893-10-7
化学式
C13H13NO3S
mdl
——
分子量
263.317
InChiKey
ATUPZSVXSGSZRI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    80.7
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    7-Methylthio-3-carbethoxy-4-chinolinol 、 sodium hydride 、 sodium hydroxide 作用下, 以 甲醇N,N-二甲基甲酰胺 为溶剂, 反应 17.17h, 生成 7-(methylthio)-1-octyl-4-quinolone-3-carboxylic acid
    参考文献:
    名称:
    Structural development of a type-1 ryanodine receptor (RyR1) Ca2+-release channel inhibitor guided by endoplasmic reticulum Ca2+ assay
    摘要:
    Type-1 ryanodine receptor (RyRI) is a calcium-release channel localized on sarcoplasmic reticulum (SR) of the skeletal muscle, and mediates muscle contraction by releasing Ca2+ from the SR. Genetic mutations of RyRI are associated with skeletal muscle diseases such as malignant hyperthermia and central core diseases, in which over-activation of RyRI causes leakage of Ca2+ from the SR. We recently developed an efficient high-throughput screening system based on the measurement of Ca2+ in endoplasmic reticulum, and used it to identify oxolinic acid (1) as a novel RyRI channel inhibitor. Here, we designed and synthesized a series of quinolone derivatives based on 1 as a lead compound. Derivatives bearing a long alkyl chain at the nitrogen atom of the quinolone ring and having a suitable substituent at the 7-position of quinolone exhibited potent RyR1 channel-inhibitory activity. Among the synthesized compounds, 14h showed more potent activity than dantrolene, a known RyR1 inhibitor, and exhibited high RyR1 selectivity over RyR2 and RyR3. These compounds may be promising leads for clinically applicable RyRI channel inhibitors. (C) 2019 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2019.06.076
  • 作为产物:
    描述:
    3-氨基茴香硫醚乙醇 为溶剂, 反应 28.0h, 生成 7-Methylthio-3-carbethoxy-4-chinolinol
    参考文献:
    名称:
    Structural development of a type-1 ryanodine receptor (RyR1) Ca2+-release channel inhibitor guided by endoplasmic reticulum Ca2+ assay
    摘要:
    Type-1 ryanodine receptor (RyRI) is a calcium-release channel localized on sarcoplasmic reticulum (SR) of the skeletal muscle, and mediates muscle contraction by releasing Ca2+ from the SR. Genetic mutations of RyRI are associated with skeletal muscle diseases such as malignant hyperthermia and central core diseases, in which over-activation of RyRI causes leakage of Ca2+ from the SR. We recently developed an efficient high-throughput screening system based on the measurement of Ca2+ in endoplasmic reticulum, and used it to identify oxolinic acid (1) as a novel RyRI channel inhibitor. Here, we designed and synthesized a series of quinolone derivatives based on 1 as a lead compound. Derivatives bearing a long alkyl chain at the nitrogen atom of the quinolone ring and having a suitable substituent at the 7-position of quinolone exhibited potent RyR1 channel-inhibitory activity. Among the synthesized compounds, 14h showed more potent activity than dantrolene, a known RyR1 inhibitor, and exhibited high RyR1 selectivity over RyR2 and RyR3. These compounds may be promising leads for clinically applicable RyRI channel inhibitors. (C) 2019 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2019.06.076
点击查看最新优质反应信息

文献信息

  • 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
    申请人:Pharmacia & Upjohn Company
    公开号:US06093732A1
    公开(公告)日:2000-07-25
    The present invention provides 4-hydroxyquinoline-3-carboxamide and hydrazide compounds of formula I ##STR1## These compounds are useful to treat or prevent the herpesviral infections, particularly, human cytomegaloviral infection.
    本发明提供了式I的4-羟基喹啉-3-甲酰胺和肼化合物。这些化合物可用于治疗或预防疱疹病毒感染,特别是人类巨细胞病毒感染。
  • [EN] 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS<br/>[FR] 4-HYDROXYQUINOLINE-3-CARBOXAMIDES ET HYDRAZIDES UTILISES COMME AGENTS ANTIVIRAUX
    申请人:PHARMACIA & UPJOHN COMPANY
    公开号:WO1999032450A1
    公开(公告)日:1999-07-01
    (EN) The present invention provides 4-hydroxyquinoline-3-carboxamide and hydrazide compounds of formula (I). These compounds are useful to treat or prevent the herpesviral infections, particularly, human cytomegaloviral infection.(FR) La présente invention concerne des composés de 4-hydroxyquinoline-3-carboxamide et d'hydrazide représentés par la formule (I). Ces composés servent dans le traitement ou la prévention d'infections à virus herpétique, en particulier, de l'infection à cytomégalovirus humain.
    本发明提供了公式(I)的4-羟基喹啉-3-羧酰胺和肼类化合物。这些化合物可用于治疗或预防疱疹病毒感染,特别是人类巨细胞病毒感染。
  • 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS
    申请人:Pharmacia & Upjohn Company LLC
    公开号:EP1042295B1
    公开(公告)日:2005-09-07
  • Design, synthesis, and biological evaluation of novel 4-hydro-quinoline-3-carboxamide derivatives as an immunomodulator
    作者:Jun-Feng He、Liu-Hong Yun、Ri-Fang Yang、Zhi-Yong Xiao、Jun-Ping Cheng、Wen-Xia Zhou、Yong-Xiang Zhang
    DOI:10.1016/j.bmcl.2005.04.040
    日期:2005.6
    A series of novel quinoline-3-carboxamide derivatives were synthesized and evaluated for their immunomodulatory activity. The compounds were tested in vitro for effects on spleen lymphocyte proliferation and TNF-alpha production by macrophage. Three compounds showed immunomodulatory profiles similar to and more potent than those of linomide and FR137316 and were selected for further pharmacological studies in vivo. (c) 2005 Elsevier Ltd. All rights reserved.
  • US6093732A
    申请人:——
    公开号:US6093732A
    公开(公告)日:2000-07-25
查看更多